Fat Loss & GH Stack

The Fat Loss & GH Stack combines two growth hormone–releasing peptides that act through distinct, complementary receptor pathways. Tesamorelin — a synthetic analog of growth hormone–releasing hormone (GHRH) — is the only peptide in this class with FDA approval (Egrifta®, 2010), indicated for reducing excess visceral abdominal fat in HIV-associated lipodystrophy. Research from randomized controlled trials has demonstrated that tesamorelin reduces visceral adipose tissue by approximately 15–18% over 6–12 months without perturbing glucose metabolism [PMID: 20101189] [PMID: 25038357]. Ipamorelin is a synthetic pentapeptide and selective ghrelin receptor (GHSR-1a) agonist — described in the literature as the first growth hormone secretagogue with a selectivity for GH release comparable to GHRH itself, without significantly elevating ACTH or cortisol [PMID: 9849822].\n\nThe scientific rationale for pairing these compounds rests on the two-signal model of growth hormone secretion. Pituitary somatotrophs integrate input from two independent receptor systems: the GHRH receptor (which drives GH gene transcription and synthesis via cAMP) and the ghrelin receptor GHSR-1a (which amplifies GH pulse amplitude by modulating somatostatin tone). Preclinical evidence suggests that simultaneous stimulation of both pathways can produce synergistic GH release — significantly greater than either signal alone [PMID: 11549707]. Tesamorelin addresses the GHRH arm; ipamorelin addresses the ghrelin arm.\n\nBoth compounds are classified as research peptides. Tesamorelin carries an FDA approval history for a specific clinical indication (HIV lipodystrophy), while ipamorelin remains investigational with no approved human therapeutic use. The information on this page reflects published scientific literature and is intended as a resource for researchers — not as guidance for human use, medical treatment, or diagnosis.

The endocrine regulation of growth hormone secretion operates through two complementary signaling axes that converge on pituitary somatotroph cells. GHRH binds its receptor on somatotrophs to activate adenylyl cyclase, increase intracellular cAMP, and drive GH gene transcription and hormone release. Ghrelin, acting through the GHSR-1a receptor, operates via a separate phospholipase C/IP₃/calcium pathway that amplifies the amplitude of individual GH pulses, partly by suppressing somatostatin-mediated inhibition [PMID: 16906274]. Research suggests that endogenous ghrelin may function as an amplifier of the basic GH pulsatile pattern, optimizing somatotroph responsiveness to GHRH [PMID: 16906274].\n\nTesamorelin is a synthetic GHRH analog (the 44-amino-acid human GHRH with a trans-3-hexenoyl group at the N-terminus) that stimulates the GHRH receptor to promote GH synthesis and release. A landmark 12-month randomized controlled trial (n=404) demonstrated that tesamorelin at 2 mg/day subcutaneous reduced visceral adipose tissue by approximately 18% compared to placebo (P < 0.0001), with significant improvements in trunk fat, waist circumference, and waist-hip ratio — and critically, without significant changes in fasting glucose [PMID: 20101189]. A subsequent JAMA-published RCT confirmed these visceral fat findings and additionally showed a significant reduction in hepatic fat (liver fat decreased by 2.0% vs. 0.9% increase in placebo, P = .003) [PMID: 25038357]. Secondary analyses further showed that tesamorelin responders experienced significant increases in skeletal muscle area and density, suggesting a favorable shift in body composition beyond fat reduction alone [PMID: 31237318].\n\nIpamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective agonist at the GHSR-1a ghrelin receptor. The seminal pharmacological characterization by Engel et al. demonstrated that ipamorelin releases GH from rat pituitary cells with potency and efficacy comparable to GHRP-6 (EC₅₀ = 1.3 nmol/L), but — critically — without releasing ACTH or cortisol even at doses exceeding 200-fold its ED₅₀ for GH release [PMID: 9849822]. This selectivity distinguishes ipamorelin from earlier growth hormone–releasing peptides (GHRP-2, GHRP-6, hexarelin), which all significantly elevate cortisol via ACTH release. Ipamorelin also preserves the natural pulsatile pattern of GH secretion, a pharmacokinetic feature researchers consider important for physiologic GH signaling [PMID: 10496658].\n\nThe research rationale for combining tesamorelin and ipamorelin draws on the well-established synergy between GHRH-pathway and ghrelin-pathway stimulation. Preclinical work by Hataya et al. showed that combined administration of GHRH and ghrelin at sub-threshold doses produced synergistic GH release — a response significantly greater than the additive effect of either peptide alone [PMID: 11549707]. Because tesamorelin and ipamorelin target the same two receptor systems (GHRH-R and GHSR-1a, respectively) without mechanistic overlap, researchers hypothesize that the combination may engage a broader and more robust GH release profile than either compound used independently. No direct clinical trial has tested this specific combination in humans, and the synergy rationale is extrapolated from independent preclinical and clinical studies on each compound.

A defining feature of this stack is that both peptides are administered via subcutaneous injection, which simplifies combined protocol design compared to stacks requiring different routes of administration. However, the two compounds differ in their studied dosing parameters. Tesamorelin has been studied at a fixed dose of 2 mg/day subcutaneous in multiple randomized controlled trials — a dose established through its clinical development program for HIV-associated lipodystrophy [PMID: 20101189] [PMID: 25038357]. Ipamorelin dosing in preclinical studies has ranged from low nanomole-per-kilogram concentrations in animal models [PMID: 9849822] to various doses explored in phase 2 human studies for postoperative ileus [PMID: 25331030].\n\nThe difference in evidence depth between the two compounds is substantial. Tesamorelin has a well-characterized human safety and efficacy profile from controlled trials spanning up to 52 weeks, with a defined FDA-approved dose. Ipamorelin's human data is more limited, with phase 2 trials in specific surgical contexts and no long-term body composition data in controlled human studies. Researchers designing combined protocols must account for this asymmetry in the available evidence base.\n\nOne approach described in the research context involves maintaining the established tesamorelin dosing schedule while adding ipamorelin at doses informed by the ghrelin-receptor agonist literature. Because both peptides have relatively short half-lives — tesamorelin's elimination half-life is approximately 26–38 minutes, while ipamorelin's GH-stimulating effect peaks at roughly 0.67 hours and declines exponentially [PMID: 10496658] — consistent daily scheduling is considered important for maintaining steady signaling exposure. Research protocols in anecdotal literature typically span 8 to 16 weeks, reflecting the time frame over which measurable body composition changes have been observed in tesamorelin clinical trials. No standardized combined protocol exists, and all available information reflects either independent clinical data on each compound or extrapolation from preclinical synergy studies.